Treatment Outcomes on Bosutinib: Data from the Real World
Jane Apperley, Imperial College, London, UK

• Change in CML survival over time: German studies 
• Patient pathways for tyrosine kinase inhibitors
• Introduction of bosutinib into clinical practice
• Real-World use of bosutinib: UK & Netherlands
• Responses to bosutinib in chronic phase
• Reasons for discontinuation of bosutinib
• Disease progression
• Adverse events on bosutinib
• Overall survival
• Summary and conclusions

This presentation is adapted from one given during the industry sponsored symposium at EHA.